secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-08-24T11:00:37+00:00
Accession:  0001628280-26-058512
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences doses first patient in Phase 1/2 FUNCTION-DMD gene editing trial
--------------------------------------------------------------------------------

- First patient dosed with PBGENE-DMD, first clinical gene-editing program for DMD, at Arkansas Children's Hospital.
- PBGENE-DMD excises exons 45-55 to restore near full-length dystrophin; applicable to up to 60% of DMD patients.
- Trial enrolling ambulatory DMD patients aged 2-7 with mutations between exons 45-55; initial safety data expected by year-end 2026.
- PBGENE-DMD is wholly owned in vivo program using ARCUS platform; aims to durably improve function.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/0001628280-26-058512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-058512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer